Frequently Asked Questions What is peptide microdosing
TPO becomes active at the apical surface of thyrocytes only after it binds a prosthetic haem group ( Reference Fayadat, Niccoli-Sire and Lanet 40 ) , hence an adequate iron status is required for the synthesis of thyroid hormones
VA users with type 2 diabetes (T2D) who used sulfonylureas or GLP-1RAs between 2017 and 2023 were identified, with follow-up extending until the outcome occurred, 3 years after treatment initiation, or 31 December 2024, whichever came first
Whether youre seeking a boost in energy, immune support, recovery after travel or illness, or help to manage chronic fatigue, IV therapy offers a fast, effective path to feeling better
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
.png.jpg)
